A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

NCT05057897 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped Removal of the commitment for Immune compromised study (D81111C00010) due to recruitment challenges.

Conditions

Interventions

Sponsor

AstraZeneca